Dr. Honeycutt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1705 E Broadway
Suite 100
Columbia, MO 65201Phone+1 573-874-7800Fax+1 573-443-3627
Summary
- Dr. Pamela Honeycutt is an oncologist based in Columbia, MO, with a comprehensive background in internal medicine, hematology, and medical oncology, having completed her residency at California Pacific Medical Center and fellowship at Duke University Hospital. She graduated from Duke University School of Medicine in 1981. Dr. Honeycutt has contributed to the field through her research, with publications including studies on metastatic renal cancer, advanced melanoma, tumor-associated antigens, and neutrophil stimulation, cited multiple times in scientific literature. She received the Meaningful Use Stage 1 Certification from the Centers for Medicare & Medicaid Services in 2012. She retired in late 2015.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1984 - 1987
California Pacific Medical CenterResidency, Internal Medicine, 1981 - 1984
Duke University School of MedicineClass of 1981
Certifications & Licensure
CA State Medical License 1982 - Present
MO State Medical License 1989 - 2026
NC State Medical License 1984 - 2005
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 4 citationsContinuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.Gamini Soori, Richard S. Schulof, James J. Stark, Michael C. Wiemann, Pamela J. Honeycutt
Cancer Investigation. 1999-01-01 - 21 citationsInterferon-α and chemohormonal therapy for patients with advanced melanoma : Final results of a phase I-II study of the cancer biotherapy research group and the mid-at...James J. Stark, Robert O. Dillman, Richard Schulof, Michael C. Wiemann, Neil M. Barth
Cancer. 1998-05-01 - 14 citationsSolubilization of complexes between tumor-associated and H-2 antigens from a tumor cell plasma membrane.Pamela J. Honeycutt, Linda R. Gooding
European Journal of Immunology. 1980-05-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
